XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
  Anti-Inflammatory
  Antivirals
  Antihypertensives
  Anticholesterol
  Anti-Clotting Drugs
  Anti Cancer Drugs
  Hypnotics
  PPI
  Antibiotics
  Analgesics
  Surfactants
  Fatty Acids
  Adrenergics
  Metals
  Varenicline
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Pharmacology Channel
subscribe to Pharmacology newsletter

Latest Research : Pharmacology

   DISCUSS   |   EMAIL   |   PRINT
FDA Approves Budesonide for the Maintenance of Remission in Crohn's disease
May 11, 2005, 09:58, Reviewed by: Dr.

"Physicians can now provide their patients with an effective long-term therapy option, in addition to an acute treatment related to mild to moderate active Crohn's disease. Our commitment is to continue to aid physicians in improving the lives of their patients through providing meaningful products and the FDA's additional approval is a significant component in keeping with that commitment."

 
Prometheus Laboratories Inc., a specialty pharmaceutical company, announced today that the U.S. Food & Drug
Administration (FDA) has approved the supplemental New Drug Application (sNDA)for the additional use of Entocort(R) EC (budesonide) Capsules for the maintenance of clinical remission of mild to moderate Crohn's disease involving the ileum and/or the ascending colon for up to three months.

Entocort EC is the only pharmacological product indicated for the treatment of mild to moderate Crohn's disease involving the ileum and/or the ascending colon, which affects nearly 70% of Crohn's patients.

"We are excited to have this additional indication for Entocort EC," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "Physicians can now provide their patients with an effective long-term therapy
option, in addition to an acute treatment related to mild to moderate active Crohn's disease. Our commitment is to continue to aid physicians in improving the lives of their patients through providing meaningful products and the FDA's additional approval is a significant component in keeping with that commitment."

The additional approval is based on the results of four double-blind, placebo-controlled, 12-month trials in which 380 patients were randomized and treated once daily with either 3 mg or 6 mg Entocort EC, or placebo. The median time to relapse in the pooled population of the 4 studies was 154 days for patients taking placebo, and 268 days for patients taking Entocort EC, at 6 mg/day.

Entocort EC at 6 mg/day significantly reduced the percentage of patients with loss of symptom control (28%) versus placebo (45%) in the pooled population for the 4 studies at three months.

Entocort EC is a topical glucocorticosteriod, working primarily in the intestines. Its specifically designed oral formulation allows local release in the ilium and the ascending colon. The adverse event profile in long-term
treatment was similar to that of short-term treatment with Entocort EC. The most common side effects of Entocort EC observed in clinical trials were headache, respiratory infection, nausea and symptoms of hypercorticism.

About Crohn's Disease

Crohn's disease is a chronic inflammatory bowel disease of unknown origin.An estimated 500,000 Americans have the disorder. Flare-ups of the disease can range from mild to severe and involve symptoms such as diarrhea, abdominal
pain, fever and sometimes rectal bleeding. The condition can be difficult to manage clinically and consumes a substantial amount of healthcare resources in terms of physician time, procedures and medications.
 

- U.S. Food and Drug Administration (FDA)
 

www.prometheuslabs.com

 
Subscribe to Pharmacology Newsletter
E-mail Address:

 

About Prometheus

Prometheus Laboratories Inc. is a specialty pharmaceutical company committed to developing new ways to help physicians individualize patient care. Prometheus focuses on the treatment, diagnosis and detection of gastrointestinal, autoimmune and inflammatory diseases and disorders. Prometheus' strategy includes the marketing and delivery of pharmaceutical products complemented by its proprietary, high-value diagnostic testing services. By integrating therapeutics and diagnostic services, Prometheus addresses the continuum of patient care, thereby providing physicians with a comprehensive solution to treat chronic diseases. Prometheus' corporate offices are located in San Diego, California. Additional information about Prometheus can be found at http://www.prometheuslabs.com.

This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent that any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and ncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors. Prometheus cautions that any forward-looking information is not a guarantee of future performance. The Company may not successfully maintain or grow the market for Entocort EC for a variety of reasons.

Entocort is a registered trademark of the AstraZeneca group of companies.


Related Pharmacology News

Phase Ib Trial Is Evaluating Bavituximab Administered With Common Chemotherapy Regimens
Two-component lantibiotic with therapeutic potential discovered
Prescription pain medication abuse on rise
Antibiotic inhibits cancer gene activity
NRTIs limits the atherogenic side effect of the protease inhibitors
Cyclin-dependent kinase inhibitors: The latest anti-inflammatory
FDA requested to promptly approve 17-P to prevent premature birth
Rapamycin shown to inhibit angiogenesis
Tigecycline, world�s first glycylcycline expanded broad-spectrum antibiotic, launched in UK
Ibuprofen - worsening cognitive function


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us